Peer Reviewed
Drug update
Micronised progesterone as a component of menopausal hormone therapy
Recent articles on:
Hormone replacement therapy
Hormone replacement therapy
Abstract
Micronised progesterone (mP) was TGA approved in 2016 for use as a progestogen in menopausal hormone therapy (MHT). It has improved bioavailability when taken orally, appears to have a more favourable breast safety profile than other progestogens, is neutral with respect to cardiovascular disease risk and does not cause adverse mood effects.
Get full access
Buy this article
Single article purchases are temporarily unavailable due to site maintenance.
If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.
Thank you for your patience and understanding.
Already a subscriber? Login here.